Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 3
2006 9
2007 12
2008 12
2009 6
2010 9
2011 9
2012 7
2013 12
2014 16
2015 10
2016 7
2017 10
2018 13
2019 5
2020 69
2021 59
2022 48
2023 36
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

349 results

Results by year

Filters applied: . Clear all
Page 19
High Potency of a Bivalent Human V(H) Domain in SARS-CoV-2 Animal Models.
Li W, Schäfer A, Kulkarni SS, Liu X, Martinez DR, Chen C, Sun Z, Leist SR, Drelich A, Zhang L, Ura ML, Berezuk A, Chittori S, Leopold K, Mannar D, Srivastava SS, Zhu X, Peterson EC, Tseng CT, Mellors JW, Falzarano D, Subramaniam S, Baric RS, Dimitrov DS. Li W, et al. Among authors: baric rs. Cell. 2020 Oct 15;183(2):429-441.e16. doi: 10.1016/j.cell.2020.09.007. Epub 2020 Sep 4. Cell. 2020. PMID: 32941803 Free PMC article.
Bivalent V(H), V(H)-Fc ab8, bound with high avidity to membrane-associated S glycoprotein and to mutants found in patients. It potently neutralized mouse-adapted SARS-CoV-2 in wild-type mice at a dose as low as 2 mg/kg and exhibited high prophylactic and therapeutic effica …
Bivalent V(H), V(H)-Fc ab8, bound with high avidity to membrane-associated S glycoprotein and to mutants found in patients. It potently neut …
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, Chen RE, Winkler ES, Wessel AW, Case JB, Kashentseva E, McCune BT, Bailey AL, Zhao H, VanBlargan LA, Dai YN, Ma M, Adams LJ, Shrihari S, Danis JE, Gralinski LE, Hou YJ, Schäfer A, Kim AS, Keeler SP, Weiskopf D, Baric RS, Holtzman MJ, Fremont DH, Curiel DT, Diamond MS. Hassan AO, et al. Among authors: baric rs. Cell. 2020 Oct 1;183(1):169-184.e13. doi: 10.1016/j.cell.2020.08.026. Epub 2020 Aug 19. Cell. 2020. PMID: 32931734 Free PMC article.
In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels of neutralizing antibodies, promotes systemic and mucosal immunoglobulin A (IgA) and T cell responses, and almost entirely prevents SARS-CoV-2 infection in both the upper and lower respir …
In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels of neutralizing antibodies, promotes systemic and muco …
Possibility for reverse zoonotic transmission of SARS-CoV-2 to free-ranging wildlife: A case study of bats.
Olival KJ, Cryan PM, Amman BR, Baric RS, Blehert DS, Brook CE, Calisher CH, Castle KT, Coleman JTH, Daszak P, Epstein JH, Field H, Frick WF, Gilbert AT, Hayman DTS, Ip HS, Karesh WB, Johnson CK, Kading RC, Kingston T, Lorch JM, Mendenhall IH, Peel AJ, Phelps KL, Plowright RK, Reeder DM, Reichard JD, Sleeman JM, Streicker DG, Towner JS, Wang LF. Olival KJ, et al. Among authors: baric rs. PLoS Pathog. 2020 Sep 3;16(9):e1008758. doi: 10.1371/journal.ppat.1008758. eCollection 2020 Sep. PLoS Pathog. 2020. PMID: 32881980 Free PMC article. Review.
The establishment of new wildlife reservoirs for SARS-CoV-2 would further complicate public health control measures and could lead to wildlife health and conservation impacts. ...Here, we review the diversity and natural host range of beta-CoVs in bats and examine the risk …
The establishment of new wildlife reservoirs for SARS-CoV-2 would further complicate public health control measures and could lead to …
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
Dinnon KH 3rd, Leist SR, Schäfer A, Edwards CE, Martinez DR, Montgomery SA, West A, Yount BL Jr, Hou YJ, Adams LE, Gully KL, Brown AJ, Huang E, Bryant MD, Choong IC, Glenn JS, Gralinski LE, Sheahan TP, Baric RS. Dinnon KH 3rd, et al. Among authors: baric rs. Nature. 2020 Oct;586(7830):560-566. doi: 10.1038/s41586-020-2708-8. Epub 2020 Aug 27. Nature. 2020. PMID: 32854108 Free PMC article.
Here we used reverse genetics(5) to remodel the interaction between SARS-CoV-2 spike protein and mouse ACE2 and designed mouse-adapted SARS-CoV-2 (SARS-CoV-2 MA), a recombinant virus that can use mouse ACE2 for entry into cells. SARS-CoV-2 MA was able …
Here we used reverse genetics(5) to remodel the interaction between SARS-CoV-2 spike protein and mouse ACE2 and designed mouse-adapte …
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2.
Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH 3rd, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D, King NP. Walls AC, et al. Among authors: baric rs. bioRxiv [Preprint]. 2020 Aug 12:2020.08.11.247395. doi: 10.1101/2020.08.11.247395. bioRxiv. 2020. PMID: 32817941 Free PMC article. Updated. Preprint.
A safe, effective, and scalable vaccine is urgently needed to halt the ongoing SARS-CoV-2 pandemic. Here, we describe the structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV- …
A safe, effective, and scalable vaccine is urgently needed to halt the ongoing SARS-CoV-2 pandemic. Here, we describe the structure-b …
De novo design of ACE2 protein decoys to neutralize SARS-CoV-2.
Linsky TW, Vergara R, Codina N, Nelson JW, Walker MJ, Su W, Hsiang TY, Esser-Nobis K, Yu K, Hou YJ, Priya T, Mitsumoto M, Pong A, Lau UY, Mason ML, Chen J, Chen A, Berrocal T, Peng H, Clairmont NS, Castellanos J, Lin YR, Josephson-Day A, Baric R, Walkey CD, Swanson R, Gale M, Blancas-Mejia LM, Yen HL, Silva DA. Linsky TW, et al. Among authors: baric r. bioRxiv [Preprint]. 2020 Aug 3:2020.08.03.231340. doi: 10.1101/2020.08.03.231340. bioRxiv. 2020. PMID: 32793910 Free PMC article. Updated. Preprint.
There is an urgent need for the ability to rapidly develop effective countermeasures for emerging biological threats, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the ongoing coronavirus disease 2019 (COVID-19) pandemic. ...Using our …
There is an urgent need for the ability to rapidly develop effective countermeasures for emerging biological threats, such as the severe acu …
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine.
Sun W, McCroskery S, Liu WC, Leist SR, Liu Y, Albrecht RA, Slamanig S, Oliva J, Amanat F, Schaefer A, Dinnon KH, Innis BL, Garcia-Sastre A, Krammer F, Baric RS, Palese P. Sun W, et al. Among authors: baric rs. bioRxiv [Preprint]. 2020 Jul 31:2020.07.30.229120. doi: 10.1101/2020.07.30.229120. bioRxiv. 2020. PMID: 32766572 Free PMC article. Updated. Preprint.
A successful SARS-CoV-2 vaccine must be not only safe and protective but must also meet the demand on a global scale at low cost. ...More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections or significantly attenuated SARS-CoV …
A successful SARS-CoV-2 vaccine must be not only safe and protective but must also meet the demand on a global scale at low cost. ... …
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Wu K, Henry C, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Stevens LJ, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Alvarado GS, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. Corbett KS, et al. Among authors: baric rs. Nature. 2020 Oct;586(7830):567-571. doi: 10.1038/s41586-020-2622-0. Epub 2020 Aug 5. Nature. 2020. PMID: 32756549 Free PMC article.
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. ...This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein t …
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-1 …
Cryo-electron Microscopy and Exploratory Antisense Targeting of the 28-kDa Frameshift Stimulation Element from the SARS-CoV-2 RNA Genome.
Zhang K, Zheludev IN, Hagey RJ, Wu MT, Haslecker R, Hou YJ, Kretsch R, Pintilie GD, Rangan R, Kladwang W, Li S, Pham EA, Bernardin-Souibgui C, Baric RS, Sheahan TP, D Souza V, Glenn JS, Chiu W, Das R. Zhang K, et al. Among authors: baric rs. bioRxiv [Preprint]. 2020 Jul 20:2020.07.18.209270. doi: 10.1101/2020.07.18.209270. bioRxiv. 2020. PMID: 32743589 Free PMC article. Updated. Preprint.
Drug discovery campaigns against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are beginning to target the viral RNA genome (1, 2) . The frameshift stimulation element (FSE) of the SARS-CoV-2 genome is required for balanced expression of essential vir …
Drug discovery campaigns against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are beginning to target the viral RNA g …
Progenitor identification and SARS-CoV-2 infection in long-term human distal lung organoid cultures.
Salahudeen AA, Choi SS, Rustagi A, Zhu J, de la O SM, Flynn RA, Margalef-Català M, Santos AJM, Ju J, Batish A, van Unen V, Usui T, Zheng GXY, Edwards CE, Wagar LE, Luca V, Anchang B, Nagendran M, Nguyen K, Hart DJ, Terry JM, Belgrader P, Ziraldo SB, Mikkelsen TS, Harbury PB, Glenn JS, Garcia KC, Davis MM, Baric RS, Sabatti C, Amieva MR, Blish CA, Desai TJ, Kuo CJ. Salahudeen AA, et al. Among authors: baric rs. bioRxiv [Preprint]. 2020 Jul 27:2020.07.27.212076. doi: 10.1101/2020.07.27.212076. bioRxiv. 2020. PMID: 32743583 Free PMC article. Updated. Preprint.
The distal lung contains terminal bronchioles and alveoli that facilitate gas exchange and is affected by disorders including interstitial lung disease, cancer, and SARS-CoV-2-associated COVID-19 pneumonia. Investigations of these localized pathologies have been hindered b …
The distal lung contains terminal bronchioles and alveoli that facilitate gas exchange and is affected by disorders including interstitial l …
349 results